CA2814057C - Intravenous composition comprising paracetamol and ibuprofen - Google Patents
Intravenous composition comprising paracetamol and ibuprofen Download PDFInfo
- Publication number
- CA2814057C CA2814057C CA2814057A CA2814057A CA2814057C CA 2814057 C CA2814057 C CA 2814057C CA 2814057 A CA2814057 A CA 2814057A CA 2814057 A CA2814057 A CA 2814057A CA 2814057 C CA2814057 C CA 2814057C
- Authority
- CA
- Canada
- Prior art keywords
- ibuprofen
- paracetamol
- approximately
- combination
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960001680 ibuprofen Drugs 0.000 title claims abstract description 49
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 title claims abstract description 47
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 title claims abstract description 47
- 229960005489 paracetamol Drugs 0.000 title claims abstract description 47
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 238000001990 intravenous administration Methods 0.000 title claims abstract description 20
- 206010061218 Inflammation Diseases 0.000 claims abstract description 9
- 230000004054 inflammatory process Effects 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- GCCOJNYCFNSJII-VWMHFEHESA-N [n'-[(4s)-4-amino-4-carboxybutyl]carbamimidoyl]azanium;2-[4-(2-methylpropyl)phenyl]propanoate Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N.CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 GCCOJNYCFNSJII-VWMHFEHESA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 2
- IHHXIUAEPKVVII-ZSCHJXSPSA-N [(1s)-5-amino-1-carboxypentyl]azanium;2-[4-(2-methylpropyl)phenyl]propanoate Chemical compound OC(=O)[C@@H](N)CCCC[NH3+].CC(C)CC1=CC=C(C(C)C([O-])=O)C=C1 IHHXIUAEPKVVII-ZSCHJXSPSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003978 infusion fluid Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- -1 pH modulators Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ589011 | 2010-11-04 | ||
| NZ58901110 | 2010-11-04 | ||
| PCT/NZ2011/000226 WO2012060719A1 (en) | 2010-11-04 | 2011-10-26 | A combination composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2814057A1 CA2814057A1 (en) | 2012-05-10 |
| CA2814057C true CA2814057C (en) | 2022-02-01 |
Family
ID=46024668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2814057A Active CA2814057C (en) | 2010-11-04 | 2011-10-26 | Intravenous composition comprising paracetamol and ibuprofen |
Country Status (27)
| Country | Link |
|---|---|
| US (5) | US20130225685A1 (de) |
| EP (1) | EP2635269B1 (de) |
| JP (2) | JP2013541583A (de) |
| KR (1) | KR101900520B1 (de) |
| CN (2) | CN107519159A (de) |
| AU (1) | AU2011324137B2 (de) |
| BR (1) | BR112013010829B8 (de) |
| CA (1) | CA2814057C (de) |
| CL (1) | CL2013001250A1 (de) |
| CO (1) | CO6771406A2 (de) |
| CY (1) | CY1123398T1 (de) |
| DK (1) | DK2635269T3 (de) |
| ES (1) | ES2742373T3 (de) |
| HR (1) | HRP20191489T1 (de) |
| HU (1) | HUE045442T2 (de) |
| LT (1) | LT2635269T (de) |
| MX (2) | MX2013005113A (de) |
| MY (1) | MY160572A (de) |
| NZ (1) | NZ609727A (de) |
| PH (1) | PH12021550804A1 (de) |
| PL (1) | PL2635269T3 (de) |
| PT (1) | PT2635269T (de) |
| RS (1) | RS59258B1 (de) |
| RU (2) | RU2707089C2 (de) |
| SG (1) | SG189319A1 (de) |
| SI (1) | SI2635269T1 (de) |
| WO (1) | WO2012060719A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2013005113A (es) | 2010-11-04 | 2013-06-03 | Aft Pharmaceuticals Ltd | Una composicion combinada. |
| US9072710B2 (en) | 2012-03-16 | 2015-07-07 | Cumberland Pharmaceuticals Inc. | Injectable ibuprofen formulation |
| WO2016008546A1 (en) * | 2014-07-18 | 2016-01-21 | Everbright Pharmaceuticals S.A.R.L. | Aqueous formulation comprising paracetamol and ibuprofen |
| KR20170066549A (ko) * | 2014-10-06 | 2017-06-14 | 큠버랜드 파마슈티컬즈 인코포레이티드 | 통증 치료를 위한 이부프로펜과 아세트아미노펜의 공동 정맥 투여 |
| WO2018192664A1 (en) | 2017-04-20 | 2018-10-25 | Hyloris Developments Sa | METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF |
| EP3651721B1 (de) | 2017-07-10 | 2024-09-04 | Gel Cap Technologies, LLC | Kapsel mit dualer freisetzung und verfahren, vorrichtungen und systeme zu ihrer herstellung |
| US11197830B2 (en) * | 2019-02-27 | 2021-12-14 | Aft Pharmaceuticals Limited | Pharmaceutical composition containing acetaminophen and ibuprofen |
| US11568752B2 (en) * | 2020-01-28 | 2023-01-31 | David Clark Company Incorporated | Gateway retrieval alert device for aircraft pushback operations |
| WO2023281089A2 (en) | 2021-07-08 | 2023-01-12 | Krka, D.D., Novo Mesto | Pharmaceutical composition comprising naproxen and paracetamol |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3990895A (en) * | 1995-12-05 | 1997-06-27 | Adcock Ingram Limited | Pharmaceutical composition comprising a skeletal muscle relaxant, a non-steroidal antiinflammatory agent and an analgesic |
| AU2002224475B2 (en) * | 2001-11-02 | 2008-01-17 | Cumberland Pharmaceuticals Inc. | Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid |
| KR101113005B1 (ko) * | 2003-03-21 | 2012-02-24 | 맥네일-피피씨, 인코포레이티드 | 비-스테로이드계 항염증성 약물 투여법 |
| SI1781277T1 (sl) * | 2004-07-07 | 2012-07-31 | Aft Pharmaceuticals Ltd | Kombinirani sestavek ki vsebuje ibuprofen in paracetamol |
| KR20060072839A (ko) * | 2004-12-23 | 2006-06-28 | 김경태 | 아세트아미노펜과 이부프로펜을 이용하여 통증조절과 해열작용을 하는 주사제 |
| US7934627B2 (en) * | 2005-10-13 | 2011-05-03 | Alcoa Inc. | Apparatus and method for high pressure extrusion with molten aluminum |
| EP2089013B1 (de) * | 2006-10-20 | 2017-09-27 | Johnson & Johnson Consumer Inc. | Kombination von acetaminophen mit ibuprofen zur behandlung von schmerzen. |
| WO2008079818A2 (en) * | 2006-12-21 | 2008-07-03 | Soluprin Pharmaceuticals, Inc. | Intravenous administration of water soluble analgesic formulations |
| US20090264530A1 (en) * | 2008-04-16 | 2009-10-22 | Nickell Robert P | Combined nsaid and acetaminophen formulation and method |
| JP2012505830A (ja) * | 2008-10-14 | 2012-03-08 | エイエフティ ファーマスーティカルズ リミテッド | 医薬品及び医薬品治療 |
| CA2754922C (en) * | 2009-03-12 | 2016-10-18 | Cumberland Pharmaceuticals Inc. | Administration of intravenous ibuprofen |
| WO2012005605A1 (en) * | 2010-07-07 | 2012-01-12 | Aft Pharmaceuticals Limited | A combination composition comprising ibuprofen and paracetamol |
| MX2013005113A (es) | 2010-11-04 | 2013-06-03 | Aft Pharmaceuticals Ltd | Una composicion combinada. |
| KR20170066549A (ko) * | 2014-10-06 | 2017-06-14 | 큠버랜드 파마슈티컬즈 인코포레이티드 | 통증 치료를 위한 이부프로펜과 아세트아미노펜의 공동 정맥 투여 |
-
2011
- 2011-10-26 MX MX2013005113A patent/MX2013005113A/es not_active Application Discontinuation
- 2011-10-26 JP JP2013537631A patent/JP2013541583A/ja active Pending
- 2011-10-26 BR BR112013010829A patent/BR112013010829B8/pt active IP Right Grant
- 2011-10-26 CN CN201710623266.5A patent/CN107519159A/zh active Pending
- 2011-10-26 WO PCT/NZ2011/000226 patent/WO2012060719A1/en active Application Filing
- 2011-10-26 KR KR1020137014178A patent/KR101900520B1/ko active IP Right Review Request
- 2011-10-26 SG SG2013026265A patent/SG189319A1/en unknown
- 2011-10-26 LT LTEP11838295.1T patent/LT2635269T/lt unknown
- 2011-10-26 NZ NZ609727A patent/NZ609727A/en unknown
- 2011-10-26 EP EP11838295.1A patent/EP2635269B1/de active Active
- 2011-10-26 RU RU2015103107A patent/RU2707089C2/ru active
- 2011-10-26 MX MX2015008709A patent/MX367209B/es unknown
- 2011-10-26 AU AU2011324137A patent/AU2011324137B2/en active Active
- 2011-10-26 ES ES11838295T patent/ES2742373T3/es active Active
- 2011-10-26 DK DK11838295.1T patent/DK2635269T3/da active
- 2011-10-26 PT PT11838295T patent/PT2635269T/pt unknown
- 2011-10-26 HU HUE11838295A patent/HUE045442T2/hu unknown
- 2011-10-26 PL PL11838295T patent/PL2635269T3/pl unknown
- 2011-10-26 CN CN2011800525659A patent/CN103298464A/zh active Pending
- 2011-10-26 MY MYPI2013001237A patent/MY160572A/en unknown
- 2011-10-26 RU RU2013123646/15A patent/RU2013123646A/ru not_active Application Discontinuation
- 2011-10-26 RS RSP20190963 patent/RS59258B1/sr unknown
- 2011-10-26 SI SI201131767T patent/SI2635269T1/sl unknown
- 2011-10-26 US US13/882,953 patent/US20130225685A1/en not_active Abandoned
- 2011-10-26 CA CA2814057A patent/CA2814057C/en active Active
-
2013
- 2013-05-06 CL CL2013001250A patent/CL2013001250A1/es unknown
- 2013-05-22 CO CO13125952A patent/CO6771406A2/es not_active Application Discontinuation
-
2015
- 2015-08-21 US US14/832,154 patent/US20160235695A1/en not_active Abandoned
-
2017
- 2017-03-22 JP JP2017055893A patent/JP6353577B2/ja active Active
-
2018
- 2018-10-01 US US16/149,109 patent/US11446266B2/en active Active
-
2019
- 2019-07-18 CY CY20191100766T patent/CY1123398T1/el unknown
- 2019-08-16 HR HRP20191489 patent/HRP20191489T1/hr unknown
-
2021
- 2021-04-08 PH PH12021550804A patent/PH12021550804A1/en unknown
-
2022
- 2022-09-13 US US17/943,708 patent/US11896567B2/en active Active
-
2024
- 2024-01-05 US US18/405,907 patent/US20240207210A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11896567B2 (en) | Combination composition | |
| AU2009304002B2 (en) | A medicinal product and treatment | |
| AU2011274652B2 (en) | A combination composition comprising ibuprofen and paracetamol | |
| CA2785360C (en) | Treating critically ill patients with intravenous ibuprofen | |
| CA2767971A1 (en) | Treating patients with intravenous ibuprofen | |
| AU2017305661B2 (en) | New use of N,N-bis-2-mercaptoethyl isophthalamide | |
| WO2012156502A2 (en) | Two component mouth rinse preparation | |
| Gonenavar et al. | High concentration Amiodarone continuous infusion induced Phlebitis: A Case Report | |
| AU2018225758A1 (en) | Methods of treating seizure disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160826 |